FDA Approves New Diabetes Drug
Posted on: Friday, 18 March 2005, 09:00 CST
FDA approves new diabetes drug
WASHINGTON, March 17 (Xinhua) -- The US Food and Drug Administration (FDA) on Thursday approved the drug Symlin for the use in addition to insulin by diabetes patients to help lower blood sugar.
The drug, made by Amylin Pharmaceuticals Inc. of San Diego, California, is intended only to be used in combination with insulin, to help lower blood sugar during the three hours after meals, the FDA said.
Symlin can be taken by adult patients with either type 1 or type 2 diabetes. But it has not been tested for use in children.
The FDA said mixing Symlin with insulin in the same syringe can affect the activity of the insulin.
Symlin therapy may lead to low blood sugar, particularly in patients with type 1 diabetes and in patients with stomach problems.
The drug's side effects include nausea, vomiting, abdominal pain, headache, fatigue and dizziness, according to the FDA.
Source: Xinhua News Agency - CEIS
Related Articles
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- FDA Approves Takeda's Diabetes Combo
- Trial Shows New Drug May Help Cancer Patients Who Need Stem Cell Transplants
- Innodia Inc Advances Lead Drug Candidate for Treatment of Type 2 Diabetes
- FDA Approves New Diabetes Drug Symlin
- Time Magazine Reports On Cinnamon Molecule With ``Insulin-Like Properties'' For Type-2 Diabetes
- Comparing the Long-Term Cost-Effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients With Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes
- Lowering BP With Medication Provides Unexpected Benefits for Heart Disease Patients With 'Normal' Blood Pressure
- Diabetic Patients With High Blood Pressure May Benefit Significantly From a Newer Beta Blocker
 |
 |
User Comments (0)
RSS Feeds